Kornimate/medical-research-clean huggingface dataset:
optimization of the skin test procedure with iodinated contrast products for certain patients suspected of immediate hypersensitivity

Conditions: Contrast Sensitivity

Summary: hypersensitivity to iodinated contrast products (icp) affects 1 to 3% of injected patients. these reactions require an allergological assessment with skin tests in order to distinguish allergic immunological mechanisms from other non-specific mechanisms. current recommendations recommend carrying out prick tests followed by intradermal reactions up to a 10th dilution. however, undiluted idrs are carried out by several teams under certain conditions, without this having been validated. experience tends to show that these idrs are relevant in certain patients to make the diagnosis without risk.


Eligibility criteria:
inclusion criteria: * major subject (≥18 years old) * subject treated in the allergology department in the period from june 1, 2020 to july 3, 2023 for suspected allergic hypersensitivity to icps and having had at least one undiluted intradermal reaction to one or more icps. * absence of written opposition in the medical file of the subject (and/or their legal representative if applicable) to the reuse of their data for scientific research purposes. exclusion criteria: * presence of opposition from the subject (and/or their legal representative if applicable) to the reuse of their data for scientific research purposes.

Keywords: contrast sensitivity iodinated contrast products allergic immunological mechanisms allergy
this study observes the usage of non-vitamin k antagonist oral anticoagulants (noacs) in elderly patients with a heart rhythm disorder in spain

Conditions: Atrial Fibrillation

Summary: this is an observational, multicenter and cross-sectional study in non-valvular atrial fibrillation (nvaf) elderly patients currently on non-vitamin k antagonist oral anticoagulant (noac) treatment for their stroke prevention.


Eligibility criteria:
inclusion criteria: * patients are willing and provide written informed consent prior to participate in this study * patients ≥ 75 years-old at the time of the study visit. * patients with a diagnosis of non-valvular atrial fibrillation (nvaf). * patients who are being treated with noac treatment according to the indication approved in the summary of product characteristics (smpc). * patients who have started the noac treatment at least 3 months prior to the study visit. exclusion criteria: patients will be excluded from participating in this study if the following criterion is met: * current participation in any clinical trial of a drug or device. * patients who have any contraindication for noac treatment, according to the smpc.
effects of j stroke myofascial release in patients with planter fasciitis

Conditions: Plantar Fascitis

Summary: the purpose of the study is to compare the effects of j stroke myofascial release on planter fascia versus ischemic release on gastrocnemius in patients with planter fasciitis.

planter fasciitis is commonly occur in athletes and females who wear flat shoes. it is caused by the loss of planter fascia flexibility that leads to mechanical overloading of fascial structures. there are some risk factors that are important to consider include age, leg length difference, inadequate footwear, inappropriate walking and running patterns and increased planter fascia thickness. planter fascia thickness more than 4mm can be considered as an indicative of planter fasciitis. myofascial soft tissue mobilization is a low load, long duration stretch to the myofascial complex technique that is given in both acute and chronic conditions which in caused by tightness and soft tissue restriction in the patients with planter fasciitis to restore length, decrease pain and to improve function. cupping therapy on gastrocnemius is a medical technique that applies negative pressure over pain areas and pressure points that alleviates pain and improve blood circulation. it could be low-cost and convenient alternative technique to treat planter fasciitis.

Eligibility criteria:
inclusion criteria: * age 18-60years * both genders * chronic pain * heel pain with current and previous diagnosis of planter faucitis * unilateral planter fascia involvement * mild to moderate heel pain with nprs pain score value between 2-6 exclusion criteria: * recent surgery to ankle joint * impaired sensations * open wound * peripheral vascular disease * recent fractures (\<6 months)

Keywords: planter fascitis j stroke myofascial release ischemic release on gastrocnemius
use of local anesthetic (0.25% bupivacaine) for pain control in pediatric cardiac catheterization

Conditions: Pain

Summary: in the cardiac diagnostic and interventional unit (cdiu) at the hospital for sick children (sickkids), minimally invasive procedures are performed to diagnose and treat a variety of congenital heart defects. procedures are performed under general anesthetic and involve inserting a catheter through the skin and into the femoral vein or artery in the groin. in addition, the use of local anesthetic as a pain control regimen just prior to the removal of femoral artery or vein sheaths is used by some but not all cardiac interventionalists. local anesthetic is infiltrated near the sheath insertion site, at the end of the procedure while the child is under general anesthetic, with the goal of decreasing pain at the insertion site and promoting comfort in the post-operative period. the use of local anesthetic depends on the choice of the individual practitioner and is not currently a routine practice for all patients. the investigators proposed research seeks to investigate whether the use of subcutaneous bupivacaine reduces pain levels in the post-operative period in children having cardiac catheterization procedures.

a number of differences in pediatric cardiac catheterization procedures exist that limit the transferability of research findings from the adult literature. for example, the majority of pediatric cardiac catheterizations are performed under general anesthetic, and femoral sheaths are removed while under general anesthetic and at the end of the procedure. in contrast in adult clinical practice, procedures are not performed under general anesthetic, and femoral sheaths are removed when patients are awake and often 4 to 6 hours after the end of the procedure. these differences limit the ability to apply research findings in adults to pediatrics, warranting further study of the effects of local anesthetic on femoral site pain in children. as well, studies in adults have examined pain only up to 20 minutes after sheath removal. we seek to investigate the impact of bupivacaine up to 6 hours after cardiac catheterization in children.

Eligibility criteria:
inclusion criteria: 1. ages 7-18 years 2. scheduled for cardiac catheterization through the femoral artery and/or vein under general anesthetic 3. ability to speak and understand english 4. no apparent cognitive impairments exclusion criteria: 1. known allergies to bupivacaine 2. impaired renal function 3. impaired hepatic function

Keywords: cardiac catheterization local anesthetic pain experienced post-operatively pediatric patients
a multi-center prospective observational biomarker study on egfrm+ non-small cell lung cancer patients with leptomeningeal metastasis

Conditions: Non-small Cell Lung Cancer; Leptomeningeal Metastasis

Summary: leptomeningeal metastasis (lm) is one of the disastrous events when managing advanced non-small cell lung cancer (nsclc) due to a grave prognosis. although intrathecal (it) chemotherapy and brain and/or spinal axis irradiation show some effects for lm in advanced nsclc, the prognosis is still poor with median survival less than 12-14 weeks. epidermal growth factor (egfr) tyrosine kinase inhibitors (tkis) showed to be effective for lm in selected nsclc patients in some retrospective research. our single-center prospective research indicated that the incidence of egfr sensitive mutations (egfrm+) in nsclc-lm patients was high and egfr-tkis showed a survival benefit for lm in egfrm+ nsclc patients. a multi-center prospective observational biomarker study will be started in 11 lung cancer center based on our single-center prospective research result. the aims of the study are to find predictive biomarkers for lm in advanced nsclc, to establish egfr-tkis based comprehensive treatment for appropriate egfrm+ lm cases, and to establish effective clinical assessment criteria for nsclc-lm egfr-tkis treatment.


Eligibility criteria:
inclusion criteria: 1. the cytological identification of malignant cells within cerebrospinal fluid (csf). 2. non-small cell lung cancer patients. 3. tumor specimens or cytology specimens can be used for the egfr gene mutation detection. 4. the entails examining cerebrospinal fluid could be obtained by lumbar puncture. 5. expected survival time is greater than 1 month. exclusion criteria: patients with radiologic evidence of lm not confirmed by positive csf cytology.

Keywords: non-small cell lung cancer leptomeningeal metastasis egfr sensitive mutations
improved diagnosis of familial hypercholesterolemia across the northland (id-fh)

Conditions: Familial Hypercholesterolemia; Cholesterol, Elevated; Genetic Disease

Summary: the overall goal of this study is to promote awareness of familial hypercholesterolemia (fh). the investigators aim to enroll patients with suspected fh into the study and will randomize them to receive usual care or motivational interview. primary study outcomes include knowledge of fh, as well as clinical and patient-reported outcomes. this study aims to promote optimal disease management and improve outcomes of fh patients.

this is a randomized 2-arm study designed to examine the impact of a personalized remote intervention that includes evidence-based risk communication and behavior change techniques with navigation. patients who meet the inclusion criteria from both essentia health (site a) and aspirus st. luke's hospital (site b) will be invited to complete the baseline survey. participants will be randomized to one of two study arms: usual care (uc) and motivational interview (mi). participant assignment occurs after completion of the baseline survey. participants randomized to receive a mi will be contacted via telephone or email to schedule a date and time when they are available to receive a video or phone call from the study coordinator. during the mi, participants will be assessed on their readiness to communicate risk with family members. a letter will be sent to the participants physician for notice of the participation in the study. a follow-up survey will be sent to participants approximately 6 months after completion of the baseline survey, in both arms of the study. the study arms will be compared with regard to awareness and treatment of fh (aim 1), as well as the uptake of cascade screening in first- and second-degree relatives (aim 2).

Eligibility criteria:
inclusion criteria: * age 2-75 years * patients with existing clinical diagnosis or suspected fh * known genetic mutation of fh * patients with an initial (pretreatment) ldl level \>190 mg/dl or total cholesterol \>300 mg/dl (age \>19 years) or ldl-c \> 160mg/dl or total cholesterol \>260 mg/dl in children age 2-19 years * patients currently taking a lipid-lowering medication and have an ldl \>124 mg/dl or total cholesterol \>195 mg/dl * capable of providing informed consent * patients should reside in minnesota, wisconsin or north dakota. exclusion criteria: * lack of research authorization * unable to provide informed consent (including non-english speaking individuals) * known medical condition other than fh that is thought to contribute to hyperlipidemia (i.e., untreated hypothyroidism, nephrotic syndrome, cholestasis hypopituitarism) * pregnant women and prisoners will also be excluded.

Keywords: cholesterol motivational interview survey cascade screening
a study to determine the seroprevalence of bordetella pertussis in adults in hungary

Conditions: Pertussis; Pertussis Vaccines

Summary: the purpose of this study is to perform an epidemiological survey of the adult population in hungary to calculate the seroprevalence of pertussis.

the protocol posting was amended to correct the detailed title. since a sample of blood will be collected from all subjects (outside of routine hospital procedure), the study does not meet gsk's definition of an observational study and hence the term "observational" was deleted from the detailed title.

Eligibility criteria:
inclusion criteria: * subjects who the investigator believes can and will comply with the requirements of the protocol. * written informed consent will be obtained from subjects prior to performing any study procedures. * males or females ≥ 18 years of age at the time of enrollment. * agreeing to collection of a blood sample for the study. exclusion criteria: • confirmed or suspected immunological disorder.

Keywords: adults hungary bordetella pertussis seroprevalence pertussis antibodies
video-based gaming therapy in pes planus rehabilitation

Conditions: Serious Game; Videogames; Pes Planus; Virtual Reality; Exergame

Summary: purpose: it is aimed to evaluate the effect of structured exercise, wii-based exergame and wii-based serious game exercise protocols on functional parameters in individuals with pes planus. method: 69 individuals with pes planus between the ages of 18-25 who met the inclusion criteria will be included in the study. pedobarographic analysis, navicular drop test, flexibility, balance, femoral anteversion and lower extremity muscle strength measurements will be performed on the participants before and after the treatment. in addition, demographic information of individuals will be recorded through a survey. after the initial evaluation, participants will be randomly assigned to one of three groups. all subjects participating in the study will be treated under the supervision of a specialist physiotherapist for a total of 18 sessions, 3 days a week for 6 weeks, 40 minutes each session. structured exercise group; short foot exercise, towel curl exercise, toe walking, heel walking, tandem walking, eccentric gastrosoleus stretching at the edge of the stairs, collecting objects from the ground with the toes, balance exercises on one foot will be performed. penguin slide, tightrople tension, tilt table, soccer heading and balance bubble games, which are balance games of the nintendo wii game console, will be played for the wii-based exergame group for 8 minutes each and a total of 40 minutes per session. for wii-based serious game group, 3 games, balance surf, balance adventure and balance maze, which are among the balance games included in the becure balance system that works integrated with the wii balance board, will be played for 40 minutes each session under the supervision of an expert physiotherapist. after the treatment, all measurements will be repeated, the difference between before and after treatment and the superiority of different treatment protocols will be tried to be determined.


Eligibility criteria:
inclusion criteria: * those between the ages of 18-25 * diagnosed with pes planus by pedobarographic evaluation * those with flexible pes planus * have more than 10 mm navicular drop * those who have not received insoles or exercise therapy before * volunteers will be included in the study. exclusion criteria: * having another soft tissue or bone problem affecting the foot and lower extremity * having any orthopedic and neurological problems affecting balance * history of surgery or trauma in the last 6 months * cardiopulmonary, visual or auditory problems * diabetic and pregnant individuals will be excluded from the study.

Keywords: exergame virtual reality pes planus videogames serious game
trial of telbivudine combination therapy vs. continued adefovir monotherapy

Conditions: Chronic Hepatitis B

Summary: the purpose of this study is to find out if taking a combination of telbivudine and adefovir or tenofovir and telbivudine can lower the amount of hepatitis b virus in patients that have been taking adefovir alone for at least 5 months and have had less than optimal responses. the safety of taking telbivudine and adefovir together or tenofovir and telbivudine together will also be studied.


Eligibility criteria:
inclusion criteria: * documented compensated chronic hepatitis b defined by clinical history compatible with chronic hepatitis b * patient is currently receiving hepsera (adefovir dipivoxil) and has received treatment continuously for a minimum of 5 months prior to screening. other inclusion criteria may apply. exclusion criteria: * patient is pregnant or breastfeeding * patient is co-infected with hepatitis c, hepatitis d or hiv * patient previously received nucleoside(tide) therapy other than adefovir * patient previously received an interferon-based treatment or an investigational agent for hepatitis b in the preceding 12 months other exclusion criteria may apply.
role of anabolic steroids on intensive care unit-acquired weakness

Conditions: Critical Illness Polyneuropathies

Summary: the researchers intend to investigate possible anabolic effects of bi-weekly exogenous testosterone administration during intensive care unit (icu) stay for up to 8 weeks. control group will receive standard icu management and will also be followed during icu stay.

for the study chronic critical patients will be included according to criterion of mechanical ventilation by orotracheal tube\> 14 consecutive days or mechanical ventilation by tracheostomy\> 8 consecutive days and that do not present exclusion criteria. patients will be randomized into two follow-up groups: intervention group with anabolic steroid and control group. the anabolic steroid intervention group will receive a bi-weekly dose of 200mg intramuscular testosterone cypionate and receive the standard treatment of nutritional therapy and physical therapy. while patients in the control group will receive only the standard treatment of nutrition and physical therapy, without addition of the anabolic drug. at the beginning of the study and weekly the patients will be evaluated in relation to the muscular profile with diaphragm ultrasound and medical research council (mrc) application. in addition to the collection of serum homograms, leukogram, lipid profile and renal function tests. weight and nutritional therapy-related data will be identified in the patient's chart regarding caloric and protein requirement and supply adequacy. in the inclusion and biweekly will be collected serum levels of free testosterone, blood count, leukogram, blood gas, renal function and liver function. nitrogen balance of patients from urinary urea will be performed. the evaluations of the groups and the intervention with the anabolic steroid will be of 8 weeks or during the period of dependence of the mechanical ventilation. after this period the patients will be monitored for the outcome: length of stay in the intensive care unit, hospital stay until discharge and clinical outcome: death or discharge.

Eligibility criteria:
inclusion criteria: * individuals older than 18 years * mechanical ventilation by orotracheal tube for more than 14 consecutive days * mechanical ventilation by tracheostomy for more than 8 consecutive days exclusion criteria: * end of life care * known hypersensitivity to formula * venous or arterial thrombosis within last 6 months: ischemic stroke, myocardial infarction, acute peripheral arterial occlusion, acute mesenteric ischemia, deep venous thromboembolism, pulmonary embolism * decompensated congestive heart failure * acute liver failure or acute on chronic liver failure * refractory shock (norepinephrine dose \>0.3 mcg/kg/min or equivalent doses of any vasoactive agent) * platelets below \<20,000 / mm3 without transfusion plan * personal history of prostate cancer * primary neuromuscular disorders such as myasthenia gravis, guillain-barré syndrome, amyotrophic lateral sclerosis, duchenne muscular dystrophy * current or prior spinal cord injury

Keywords: prolonged mechanical ventilation critically ill patients anabolic steroid
the role of dlotca-g in the cognitive function evaluation of parkinson's patients

Conditions: Parkinson Disease

Summary: the purpose of this study is to evaluate the usefulness of dynamic loewenstein's occupational therapy and cognitive assessment scale for geriatrics (dlotca-g) in parkinson patients.

the purpose of this study to evaluate the usefulness of dynamic loewenstein's occupational therapy and cognitive assessment scale for geriatrics (dlotca-g) in the early detection of cognitive impairment in parkinson patients aged 65 and over, with and without dementia.the investigators also aimed to compare the mini mental state assessment test with dlotca-g.

Eligibility criteria:
inclusıon criteria * parkinson's patients aged 65 years and older with and without cognitive impairment (60 patients) and healthy control patients (30 patients) * hoehnn yahr staging between 1 and 2.5 in patients with parkinson's diseas * confirmed by brain mri from patients without vascular dementia who routinely attend the parkinson's follow-up outpatient clinic * at least primary school graduates * in patients with parkinson's dissease patients with cognitive impairment, mmse below 20 in primary school education level; below 24 in secondary, high school and university education level * in patients with parkinson's disease without cognitive impairment, mmse 20 and above in primary school education level; 24 and above in secondary, high school and university education level exclusıon criteria * preexisting cognitive impairment * psychiatric disorders such as psychotic disorders, mood disorders, alcohol or drug abuse * severe language dysfunction and/or bilateral limb motor dysfunction and inability to participate in clinical psychology tests, severe visual and/or auditory impairments * patients with significant cerebral atrophy or neurological vascular lesions * the geriatric depression scale was administered to all participants, and participants with a total score of 13 or more out of 30 points were excluded from the study.

Keywords: parkinson disease dlotca-g
to evaluate the efficacy of eleutherococcus senticosus for subjects under renal dialysis

Conditions: Renal Dialysis

Summary: this is a randomized, double-blind, placebo-controlled, parallel comparison trial to evaluate the efficacy and safety of eleutherococcus senticosus taken orally by patients under regular dialysis. eligible subjects with written consent were randomized into one of the two groups: a. acanthopanax senticosus (30mg/vial); b. placebo. after 2-4 weeks of run-in period, the study subjects were asked to take the investigational products orally for 90 days in order to evaluate the effects of oral eleutherococcus senticosus liquid on the markers of inflammation, anemia, and safety, and to compare the efficacy among oral acanthopanax senticosus and placebo.


Eligibility criteria:
inclusion criteria: * under regular dialysis for at least 3 months * hemoglobin (hb) \<11 g/l after regular erythropoietin (epo) treatment * subjects with written informed consent form exclusion criteria: * use of steroid or high dose of antiplatelet drug (e.g. aspirin \>300mg) within one month * had surgery, myocardial infarction, or tumor within 12 weeks * currently use of antibiotic treatment for acute infection * pregnant women * reticulocyte\>40 x 10\^9 * anemia (ferritin \<100ng/ml and transferrin saturation (tsat) \<20%) * urea reduction ratio \<65% or single pool kt/v \< 1.0 (hemodialysis patients) or total weekly kt/v\<1.7 (peritoneal dialysis patients) * sudden change of eating habit within one month * expected life less than six months or with unstable medical conditions * known history of allergic reaction to the investigational products * with acute diseases and judged by the investigator to be ineligible to participate * received melatonin, androgen therapy or blood transfusion within two months * received any trial medications within 30 days